Publications by authors named "Noelia Sanmamed-Salgado"
Article Synopsis
- Oligometastatic prostate cancer (OMPC) sits between localized and widely metastatic disease, showcasing a mix of biological characteristics and clinical behavior.
- Recent advancements in imaging allow for earlier detection of OMPC, prompting a shift towards more aggressive treatment strategies for potentially curable patients.
- A multimodal treatment approach is crucial, combining local and systemic therapies, but more research is essential to identify which patients would benefit the most from specific treatments.
Objectives: To assess whether free PSA ratio (FPSAR) at biochemical recurrence (BCR) can predict metastasis, castrate-resistant prostate cancer (CRPC), and cancer-specific survival (CSS), following therapy for localised disease.
Patients And Methods: A single-centre retrospective cohort study (NCT03927287) including a discovery cohort composed of patients with an FPSAR after radical prostatectomy (RP) or radiotherapy (RT) between 2000 and 2017. For validation, an independent Biobank cohort of patients with BCR after RP was tested.
Introduction: Digital rectal examination (DRE) is part of the clinical evaluation of men on active surveillance (AS). The purpose of the present study is to analyze the value of DRE as a predictor of upgrading in a population of men with prostate cancer (PCa) treated with AS.
Methods: We used the prostate biopsy (PBx) database from an academic center, including PBx from 2006-2018, and identified 2029 confirmatory biopsies (CxPBx) of men treated with AS, of which 726 men had both diagnostic (initial) and CxPBx information available.